Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2209)	2/1/2008 1:41:26 PM
From: Jibacoa	Respond to of 3722

BAYRY Is starting to close its Jan22 DG bigcharts.marketwatch.com Its anti-coagulant Xarelto seems to be a promising products in late-stage development. BAYRY lately has increased its reliance on pharmaceuticals. Its Xarelto's PIII data released late last Yr.,showed it to be more effective than SNLF.L's Lovenox, at preventing phlebothrombosis after orthopedic surgery. BAYRY has filed an NDA with the EMEA & plans for possible launch in 2009, it also plans to file an NDA to the FDA in 2008.(JNJ has marketing rights for the U.S.)It is expected that on approval, the 1st Yr. post-launch sales could total $120M with a much larger amount if Xarelto can be approved for active treatment in AF & DVT. Back in Sep., BAYRY received FDA approval for expanded labeling of its Campath for treatment of B-cell CLL. The stock is trading around 3.70xBV with a +CF of about $7.80 The stock has 4Qs of double digit improvements on revenues & earnings. The EE for 2007 are around $5.34 about 30% > the $4.11 in 2006 & for 2008 another 15% improvement is expected. BAYRY seems to have support at the $75 level & to have a good chance of retesting its Jan 8 H at $96.83 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2209)	1/6/2010 3:35:17 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

AFFX seems to have found support at the $6 level in spite of its recent "downgrades".<g> bigcharts.marketwatch.com In the 3rdQ it reported 4% better revenues and was able to trim some its loss. But for the YR it is still expected to have a loss around $0.48 vs. $0.33 in 2008 and fro 2010 the loss is still projected around $0.15 The stock still could close some of the DG of Oct22 above the $8 level. But at the $8 level I am looking to buy some AMRI in spite of its losses in the last 3Qs.<g> AMRI is trading below BV and has +CF and the SR which has increased lately is around 11.2x its ADV.If the EE are correct it is supposed to report on the black next Yr. for a 460% improvement on the bottom line<g> AFFX has a good size LTD, trades around 1.4xBV and has smaller +CF Recently AFFX has been performing better lately. finance.yahoo.com^ixic;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined But from a longer term view, AMRI has been more consistent.<g> finance.yahoo.com^ixic;indicator=volume;charttype Bernard